Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR

Company Acquires Phase II-Ready Prothena Drug

 
• By Alaric DeArment
Anatomy of Human Heart
Novo Nordisk has sought to broaden its reach beyond obesity and diabetes and move into areas like cardiology • Source: Shutterstock

More from Deals

More from Business